Roots Analysis has announced the addition of “Regulatory T-Cell (Tregs) Therapies Market, 2021 – 2035” report to its list of offerings.

Given the various benefits offered, including high target specificity, customization potential and ability to generate immunological memory, regulatory T-cell (Treg) therapies have garnered significant attention among key industry stakeholders for the treatment of various oncological and non-oncological disease indications.

To order this 145+ page report, which features 90+ figures and 60+ tables, please visit https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-m...

Key Market Insights

Over 90 Treg cell therapies are being evaluated to target multiple target indications
Around 40% of the Treg cell therapies are in preclinical / discovery phase. Majority (49%) of these candidates are being developed for the treatment of oncological and autoimmune disorders. Further, most (81%) of the pipeline candidates are being evaluated as monotherapies, followed by those being developed in combination with other therapeutic agents (19%)

Presently, over 80 companies claim to be engaged in the development of Treg cell therapies
Majority of the firms (56%) are large companies, followed by small players (29%) and mid-sized (15%) firms. In addition, close to 65% of the stakeholders were established before 2000. Further, around 70% of the total firms are based in Asia Pacific and North America.

Over 180 clinical trials evaluating Treg cell therapies have been registered in the last two decades
Majority (57%) of the trials investigating Treg cell therapies are ongoing / planned. Further, over 70% of the total trials registered in this domain were / are being sponsored by governmental agencies, organizations and universities.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-m...
Key Questions Answered

 What are the prevalent R&D trends related to Treg cell therapies?
 Which are the key therapeutic areas currently being targeted by Treg cell therapies?
 What are the key challenges faced by stakeholders engaged in this domain?
 Who are the leading industry and non-industry players engaged in the development of Treg cell therapies?
 What are the key geographies where research focused on Treg cell therapies is being conducted?
 What are the key value drivers that are likely to influence the evolution of this upcoming market?
 How is the current and future market opportunity likely to be distributed across key market segments?

For additional details, please visit
https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-m... or email [email protected]
You may also be interested in the following titles:
1. CD47 Targeting Therapeutics Market: Industry Trends and Global Forecasts, 2021-2030
2. Antibody Drug Conjugates Market (6th Edition): Industry Trends and Global Forecasts, 2021-2030
3. Novel T-Cell Immunotherapies Market: Industry Trends and Global Forecasts, 2021-2030
4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
5. Peptide Therapeutics Market: Industry Trends and Global Forecasts, 2021-2030
6. CRISPR Based Therapeutics Market: Focus on Cartridges, Syringes and Vials
(2nd Edition), 2021-2030

Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]